Clinical Trial

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Suspended Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Pending Interim Analysis
Summary
This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). MiRisten may stop the growth of cancer cells by blocking some of the molecules needed for cell growth. Giving miRisten may be safe, tolerable and/or effective in treating patients with relapsed or refractory AML.
Protocol Amendment History 4 changes
critical Recruitment suspended 2026-07-15
critical Recruitment suspended 2026-06-12
notable Primary completion pushed: 2027-04-08 -> 2028-03-01 2026-06-06
minor Completion pushed: 2027-04-08 -> 2028-08-01 2026-06-06
Trial Details
NCT Number NCT07025564
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Enrollment 20 participants
Start Date 2025-10-24
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24